- Home
- SYRA vs QLGN Comparison
SYRA vs QLGN Comparison
Compare SYRA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRA
- QLGN
- Stock Information
- Founded
- SYRA 2020
- QLGN 1996
- Country
- SYRA United States
- QLGN United States
- Employees
- SYRA N/A
- QLGN N/A
- Industry
- SYRA Other Specialty Stores
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SYRA Industrials
- QLGN Health Care
- Exchange
- SYRA Nasdaq
- QLGN Nasdaq
- Market Cap
- SYRA 3.5M
- QLGN 3.4M
- IPO Year
- SYRA 2023
- QLGN N/A
- Fundamental
- Price
- SYRA $0.39
- QLGN $4.09
- Analyst Decision
- SYRA
- QLGN
- Analyst Count
- SYRA 0
- QLGN 0
- Target Price
- SYRA N/A
- QLGN N/A
- AVG Volume (30 Days)
- SYRA 247.7K
- QLGN 51.7K
- Earning Date
- SYRA 10-29-2024
- QLGN 11-14-2024
- Dividend Yield
- SYRA N/A
- QLGN N/A
- EPS Growth
- SYRA N/A
- QLGN N/A
- EPS
- SYRA N/A
- QLGN N/A
- Revenue
- SYRA $7,741,558.00
- QLGN N/A
- Revenue This Year
- SYRA $47.74
- QLGN N/A
- Revenue Next Year
- SYRA N/A
- QLGN N/A
- P/E Ratio
- SYRA N/A
- QLGN N/A
- Revenue Growth
- SYRA 35.47
- QLGN N/A
- 52 Week Low
- SYRA $0.34
- QLGN $3.34
- 52 Week High
- SYRA $8.37
- QLGN $30.50
- Technical
- Relative Strength Index (RSI)
- SYRA 44.58
- QLGN 41.77
- Support Level
- SYRA $0.36
- QLGN $3.53
- Resistance Level
- SYRA $0.43
- QLGN $4.39
- Average True Range (ATR)
- SYRA 0.04
- QLGN 0.35
- MACD
- SYRA -0.00
- QLGN 0.06
- Stochastic Oscillator
- SYRA 21.12
- QLGN 43.91
About SYRA Syra Health Corp.
Syra Health Corp is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. It strives to offer comprehensive end-to-end solutions in health education services, population health management, behavioral and mental health, healthcare workforce and digital health.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.